Enriching cancer pharmacology with drugs of marine origin.

Article Details

Citation
Copy to clipboard

Jimenez PC, Wilke DV, Branco PC, Bauermeister A, Rezende-Teixeira P, Gaudencio SP, Costa-Lotufo LV

Enriching cancer pharmacology with drugs of marine origin.

Br J Pharmacol. 2020 Jan;177(1):3-27. doi: 10.1111/bph.14876. Epub 2019 Dec 23.

PubMed ID
31621891 [ View in PubMed
]
Abstract

Marine natural products have proven, over the last half-century, to be effective biological modulators. These molecules have revealed new targets for cancer therapy as well as dissimilar modes of action within typical classes of drugs. In this scenario, innovation from marine-based pharmaceuticals has helped advance cancer chemotherapy in many aspects, as most of these are designated as first-in-class drugs. Here, by examining the path from discovery to development of clinically approved drugs of marine origin for cancer treatment-cytarabine (Cytosar-U(R)), trabectedin (Yondelis(R)), eribulin (Halaven(R)), brentuximab vedotin (Adcetris(R)), and plitidepsin (Aplidin(R))- together with those in late clinical trial phases-lurbinectedin, plinabulin, marizomib, and plocabulin-the present review offers a critical analysis of the contributions given by these new compounds to cancer pharmacotherapy.

DrugBank Data that Cites this Article

Drugs